Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform


Out of Business LATEST DEAL TYPE

Developer of a diabetes treatment therapy intended to cure Type I diabetes. The company;s therapy uses gene named Diatagene that is delivered through an intravenous injection that utilizes DNA sequencing, enabling doctors to promote the activation of insulin gene within diabetic patient to help curb Type 1 diabetes.

Ownership Status
Out of Business
Financing Status
Formerly Angel backed
Primary Industry
Primary Office
  • 3330 University Avenue
  • Suite 120
  • Madison, WI 53705
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Insulete’s full profile, request a free trial.

Insulete Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-Dec-2016 00000 Completed Out of Business
2. Angel (individual) 10-May-2016 00000 00000 Completed Startup
1. Grant Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Insulete Executive Team (4)

Name Title Board
Jay Handy Co-Founder, Board Member & Acting Chief Executive Officer
Hans Sollinger MD Co-Founder, President, Chief Executive Officer & Board Member
Tausif Alam Ph.D Chief Financial Officer, Chief Scientist & Board Member
Jeffrey Rusinow Executive Officer & Chairman

Insulete Board Members (3)

Name Representing Role Since Contact
Hans Sollinger MD Insulete Co-Founder, President, Chief Executive Officer & Board Member 000 0000
Jeffrey Rusinow Insulete Executive Officer & Chairman 000 0000
Tausif Alam Ph.D Insulete Chief Financial Officer, Chief Scientist & Board Member 000 0000